Kefei Dou

1.5k total citations
100 papers, 877 citations indexed

About

Kefei Dou is a scholar working on Surgery, Cardiology and Cardiovascular Medicine and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Kefei Dou has authored 100 papers receiving a total of 877 indexed citations (citations by other indexed papers that have themselves been cited), including 83 papers in Surgery, 65 papers in Cardiology and Cardiovascular Medicine and 31 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Kefei Dou's work include Coronary Interventions and Diagnostics (62 papers), Acute Myocardial Infarction Research (41 papers) and Cardiac Imaging and Diagnostics (31 papers). Kefei Dou is often cited by papers focused on Coronary Interventions and Diagnostics (62 papers), Acute Myocardial Infarction Research (41 papers) and Cardiac Imaging and Diagnostics (31 papers). Kefei Dou collaborates with scholars based in China, United States and United Kingdom. Kefei Dou's co-authors include Yuejin Yang, Bo Xu, Dong Yin, Shubin Qiao, Yongjian Wu, Chenxi Song, Ji Huang, Shi-jie You, Hongbing Yan and Runlin Gao and has published in prestigious journals such as SHILAP Revista de lepidopterología, Journal of the American College of Cardiology and Scientific Reports.

In The Last Decade

Kefei Dou

93 papers receiving 865 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Kefei Dou China	15	546	463	215	143	106	100	877
Ota Hlinomaz Czechia	16	628 1.2×	653 1.4×	144 0.7×	135 0.9×	124 1.2×	65	1.1k
Socrates Korovesis Greece	16	391 0.7×	523 1.1×	260 1.2×	109 0.8×	141 1.3×	44	1.1k
Yen‐Wen Liu Taiwan	13	327 0.6×	516 1.1×	218 1.0×	66 0.5×	109 1.0×	35	878
Friedhelm Kuethe Germany	16	570 1.0×	566 1.2×	261 1.2×	67 0.5×	231 2.2×	29	1.1k
Noémi Pávó Austria	23	517 0.9×	1.1k 2.5×	158 0.7×	189 1.3×	228 2.2×	102	1.7k
Robbert de Winter Netherlands	16	428 0.8×	410 0.9×	91 0.4×	162 1.1×	209 2.0×	45	984
Yutaka Hikichi Japan	21	751 1.4×	508 1.1×	291 1.4×	292 2.0×	173 1.6×	57	1.2k
Jianying Ma China	13	286 0.5×	359 0.8×	174 0.8×	73 0.5×	270 2.5×	73	814
Genshan Ma China	16	274 0.5×	289 0.6×	140 0.7×	155 1.1×	130 1.2×	64	748
Zuo‐Xiang He China	18	307 0.6×	647 1.4×	534 2.5×	222 1.6×	178 1.7×	60	1.5k

Countries citing papers authored by Kefei Dou

Since Specialization

Citations

This map shows the geographic impact of Kefei Dou's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kefei Dou with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kefei Dou more than expected).

Fields of papers citing papers by Kefei Dou

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kefei Dou. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kefei Dou. The network helps show where Kefei Dou may publish in the future.

Co-authorship network of co-authors of Kefei Dou

This figure shows the co-authorship network connecting the top 25 collaborators of Kefei Dou. A scholar is included among the top collaborators of Kefei Dou based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kefei Dou. Kefei Dou is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Ni, Dongsheng, Shuang Ma, Yuefeng Wang, et al.. (2025). Membrane-associated ring–CH–type finger 2 protects against metabolic dysfunction-associated fatty liver disease by targeting fatty acid synthase. Molecular Metabolism. 96. 102137–102137.

Xie, Enmin, et al.. (2025). Validation of the role of apolipoproteins in coronary artery disease patients with impaired kidney function for prognosis: a prospective cohort study in China. Nutrition Journal. 24(1). 11–11. 1 indexed citations

Zhao, Yanyan, Yang Wang, Zening Jin, et al.. (2025). Cost-effectiveness of angiographic quantitative flow ratio-guided coronary intervention: A multicenter, randomized, sham-controlled trial. Chinese Medical Journal. 138(10). 1186–1193. 1 indexed citations

Li, Bowen, et al.. (2024). Insulin-based or non-insulin-based insulin resistance indicators and risk of long-term cardiovascular and all-cause mortality in the general population: A 25-year cohort study. Diabetes & Metabolism. 50(5). 101566–101566. 6 indexed citations

Zhang, Dong, Ruohua Yan, Haoyu Wang, et al.. (2024). Technological Advances Are Associated With Better Clinical Outcomes of Percutaneous Coronary Intervention in Patients With Unprotected Left Main Disease. Journal of the American Heart Association. 13(16). e033929–e033929. 1 indexed citations

Zhang, Shuang, Zheng Yin, Jian‐Jun Li, et al.. (2023). LDL‐C rebound after long‐term evolocumab treatment and intravascular imaging evidence in a familial hypercholesterolemia patient with early‐onset myocardial infarction. Chronic Diseases and Translational Medicine. 10(1). 69–74.

Gao, Guofeng, Haoyu Wang, Yanjun Song, et al.. (2023). Feasibility and Safety of Drug-Coated Balloon for Treatment of De Novo Coronary Artery Lesions in Large Vessel Disease: A Large-Scale Multicenter Prospective Study. Reviews in Cardiovascular Medicine. 24(10). 277–277.

Wang, Haoyu, et al.. (2022). Effect of type 2 diabetes on coronary artery ectasia: smaller lesion diameter and shorter lesion length but similar adverse cardiovascular events. Cardiovascular Diabetology. 21(1). 9–9. 2 indexed citations

Cao, Ye‐Xuan, Sha Li, Huihui Liu, et al.. (2022). Prognostic Value of N-Terminal Pro-B-Type Natriuretic Peptide and High-Sensitivity C-Reactive Protein in Patients With Previous Myocardial Infarction. Frontiers in Cardiovascular Medicine. 9. 797297–797297. 3 indexed citations

10.

Wang, Haoyu, Bo Xu, Kefei Dou, et al.. (2021). Implications of Periprocedural Myocardial Biomarker Elevations and Commonly Used MI Definitions After Left Main PCI. JACC: Cardiovascular Interventions. 14(15). 1623–1634. 36 indexed citations

11.

Liu, Mingming, Huihui Liu, Yuan‐Lin Guo, et al.. (2021). Association of circulating proprotein convertase subtilisin/kexin type 9 concentration, prothrombin time and cardiovascular outcomes: a prospective cohort study. Thrombosis Journal. 19(1). 90–90. 7 indexed citations

12.

Wang, Haoyu, Kefei Dou, Changdong Guan, et al.. (2021). IMPLICATIONS OF PERIPROCEDURAL MYOCARDIAL BIOMARKER ELEVATIONS AND COMMONLY USED MI DEFINITIONS AFTER LEFT MAIN PCI. Journal of the American College of Cardiology. 77(18). 1076–1076. 4 indexed citations

13.

Xi, Ziwei, Jianan Li, Hong Qiu, et al.. (2021). Ticagrelor vs. Clopidogrel After Complex Percutaneous Coronary Intervention in Patients With Stable Coronary Artery Disease. Frontiers in Cardiovascular Medicine. 8. 768190–768190. 5 indexed citations

14.

Wang, Haoyu, Kefei Dou, & Bo Xu. (2020). PERCUTANEOUS CORONARY INTERVENTION COMPLEXITY AND RISK OF ADVERSE EVENTS IN RELATION TO HIGH BLEEDING RISK AMONG PATIENTS RECEIVING DRUG-ELUTING STENTS: INSIGHTS FROM A LARGE SINGLE-CENTER COHORT STUDY. Journal of the American College of Cardiology. 75(11). 1377–1377. 1 indexed citations

15.

Han, Xu, Chenxi Song, Bo Xu, et al.. (2020). A Scoring System to Predict No-Reflow Phenomenon in Elective Percutaneous Coronary Intervention: The RECOVER Score. Current Problems in Cardiology. 46(3). 100676–100676. 3 indexed citations

16.

Wang, Haoyu, et al.. (2020). Risk/Benefit Tradeoff of Prolonging Dual Antiplatelet Therapy More Than 12 Months in TWILIGHT-Like High-Risk Patients After Complex Percutaneous Coronary Intervention. The American Journal of Cardiology. 133. 61–70. 4 indexed citations

17.

Wang, Juan, Changdong Guan, Jue Chen, et al.. (2020). Validation of bifurcation DEFINITION criteria and comparison of stenting strategies in true left main bifurcation lesions. Scientific Reports. 10(1). 10461–10461. 12 indexed citations

18.

Li, Xiangdong, et al.. (2013). Protein kinase A-mediated cardioprotection of Tongxinluo relates to the inhibition of myocardial inflammation, apoptosis, and edema in reperfused swine hearts. Chinese Medical Journal. 126(8). 1469–1479. 26 indexed citations

19.

Yang, Yanmin, Ji Huang, Yong‐Jian Geng, et al.. (2008). Atorvastatin treatment improves survival and effects of implanted mesenchymal stem cells in post-infarct swine hearts. European Heart Journal. 29(12). 1578–1590. 103 indexed citations

20.

Qian, Haiyan, Yuejin Yang, Jianjun Li, et al.. (2007). The role of vascular stem cells in atherogenesis and post-angioplasty restenosis. Ageing Research Reviews. 6(2). 109–127. 18 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact